tucatinib,trastuzumab
seagen,roche
['solid tumor', 'urothelial', 'sclc', 'sgntuc-019', 'trastuzumab,(-trastuzumab deruxtecan),(-trastuzumab-deruxtecan)', 'tucatinib', 'nsclc', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'breast', 'basket study', ' uc,(-ucsd),(-ucsf),']
tip: ph 2 basket study of tucatinib and trastuzumab in previously treated solid tumors with her2 alterations: sgntuc-019 #gu23 uc cohort - enrolling 12 response-evaluable pts per recist 1.1 if 2 resp --&gt; expand to 30 prim obj: antitumor activity 
Uro Onc @GACancerCenter | Res PD & Ronald W. Lewis MD Chair of Uro Educ @mcg_urology | Digital Media Ed @EUplatinum | #mentalhealth research | @urotoday